Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
ETS1 (v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)) is the most representative member of the ETS family and belongs to the first subfamily of the ETS family. The human ETS1 gene is located on chromosome 11q23.3 and encodes a protein with a relative molecular weight of 54 kD. As a transcription factor, ETS1 contains multiple functional regions, in which the transcriptional activation region (C region) is located at the center of the molecule, and the ETS region (region E) that binds to the target gene is located at the carboxyl terminus. Two regions of inhibition (D and F) are located on both sides of the ETS region, and the inhibitory region negatively regulates the binding of transcription factors to DNA. The activation mechanism of ETS1 may be mainly amplification, chromosomal translocation, and rearrangement. Studies have shown that activated ETS1 plays a major role in tumor cell proliferation, differentiation, apoptosis, tumor angiogenesis, and tumor invasion.
Regulation of ETS1
ETS1 has many physiological functions and is widely involved in the regulation of cell growth and apoptosis. Many growth factors, growth factor receptors, and integrins regulate cell growth and proliferation by the ETS1 gene. On the one hand, the ETS1 gene directly controls receptors such as granulocyte-macrophage colony stimulating factor receptors (GM-CSFR), granulocyte colony-stimulating factor receptors (G-CSFR), Toll-like receptors (Toll-like R), interleukin-2 (IL-2), and macrophage colony-stimulating factor receptors (M-CSFR), etc. to achieve its regulation of cell growth and apoptosis. On the other hand, the ETS1 gene can be regulated by other growth factors and their receptors, such as lipopolysaccharide (LPS), which stimulates ETS1 binding to TNFα promoter to exert the regulation of cell growth and apoptosis.
Nie et al. have shown that ETS1 is required for both cardiac heart palsy (NC) and cardiac mesoderm, which is essential for normal heart development. In addition, strict control of B cell differentiation into plasma cells (PC) is essential for proper immune response and prevention of autoimmunity. The role of the ETS1 transcription factor in B cells is to prevent PC differentiation.
ETS1 and Cancer
ETS1 is important in a variety of biological processes such as development, differentiation, proliferation, apoptosis, migration, and tissue remodeling. It acts as an oncogene that controls the invasive and angiogenic behavior of malignant cells in a variety of human cancers. In particular, ETS1 disorders have been reported in diffuse large B-cell lymphoma, Burkitt's lymphoma, and Hodgkin's lymphoma.
Dittmer believes that ETS1 has a selective effect in cancer and endothelial cells, as shown in Figure 1. (A) The potential role of ETS1 in EMT. EMT induction of TGFβ or HGF also results in increased expression of ETS1. ETS1 cooperates with Twist to induce the expression of ZEB1, which in turn reduces the expression of miR200 by ZEB1- and ETS1. This produced a ZEB1 / ETS1 amplification loop that promotes EMT. (B) The potential role of ETS1 in drug resistance. Once the ETS1 expression is up-regulated in cancer cells, ETS1 is able to increase the expression of various proteins involved in drug resistance, including MDR1 (multidrug resistance gene 1), CRYAB (αB-crystallin), chemokine receptor CXCR4Or glutathione upregulates the genes xCT and Gpx-1 (glutathione peroxidase 1). These proteins help to desensitize cells by lowering the level of cellular ROS (reactive oxygen species) or by blocking apoptosis through a caspase 3-dependent mechanism by pumping the drug out of the cell. (C) The potential role of ETS1 in neovascularization. ETS1 expression in endothelial cells can be induced by a number of factors, such as VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor) and the like.
Figure 1. Selected effects of ETS1 in cancer (A and B) and endothelial cells (C). (Dittmer, et al. 2015)
Studies have shown that the expression of ETS1 is closely related to the occurrence, invasion, and metastasis of digestive tract tumors. Its role as a transcription factor in tumor metastasis and angiogenesis is mainly achieved by transcriptional activation of certain enzymes that degrade extracellular matrix (ECM). These enzymes include matrix metalloproteinases (MMPs), serine proteases and the like. The study used the Ultravision polymer system to test 117 colon adenomas and 149 colon adenocarcinoma tissues. The positive rate of ETS1 in adenomas was 22. 4%, and in adenocarcinomas it was 56.3%. The results of this study demonstrate the relevance of ETS1 to the development and progression of colon cancer from different perspectives. The expression of the ETS1 protein was determined by immunohistochemical staining of 54 gastric cancer tissues, 41 lymph node metastases and 32 control groups by gastric cancer tissue microarray. The results showed that the positive rates of ETS1 gene expression in gastric cancer tissues, paracancerous tissues, and control groups were 71.4%, 29.6%, and 18.8%, respectively. The difference between the three groups was statistically significant (P<0.01).
ETS1-Mediated Cell Signal Transduction
ETS1 has a conserved DNA binding domain at the C-terminus and a pointed domain at the N-terminus and contains a MAPK phosphorylation site that is closer to the pointed domain. Phosphorylation of these sites enhances their transcriptional function. This function is achieved by combining the Ras effect components (RREs) and serum response elements (SREs) on the early response gene promoter. In addition, ETS1 plays an important role in the TGF-β signal transduction pathway by acting on transforming growth factor-β (TGF-β) receptors. The JAK/STAT signaling pathway also regulates the function of ETS1. The RAS/ERK pathway is usually activated in cancer and promotes tumorigenesis by altering transcriptional programs. Plotnik et al. showed that ETS1 is required for RAS/ERK pathway activation and that ETS1 has a dual role in mediating epithelial-specific RAS/ERK transcriptional function.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.